Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
This study is an investigator-initiated, phase II, single arm, open label clinical trial that
will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at moderate or high
risk for poor outcome, defined as an NCCN-IPI score of 2 or higher. All subjects will receive
investigational drug, and outcomes will be compared to historical controls.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio